Epilepsy Foundation, Intellimedix, Pfizer Partner on Personalized Epilepsy Drug Discovery | GenomeWeb

NEW YORK (GenomeWeb) – The Epilepsy Foundation has teamed with Pfizer and Intellimedix to create a drug discovery platform targeted toward patients with genetic forms of epilepsy, the foundation said today.

The partners hope the drug screening platform will be used to create individualized treatments for people with Dravet Syndrome, a severe form of genetic epilepsy, and for other types of this disease for which there are only limited treatment options.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.